| Literature DB >> 31313057 |
Yan Wang1, Wei Li2, Jun Yang3, Mijuan Zhang1,3, Chun'e Tian1,3, Minjiang Ma1,3, Qian Zhang1.
Abstract
Ischemic stroke is a disease that affects people's health and quality of life. Cystatin C has been found as a new biomarker of cardiovascular disease. We performed this meta-analysis to assess the relationship between cystatin C and the risk of ischemic stroke. The studies on looking at the association between cystatin C and ischemic stroke were identified from inception to November 18, 2018. We performed a random-effects meta-analysis using mean difference. Nine studies with a total of 3773 ischemic stroke patients were included into the meta-analysis. Our results showed that patients with ischemic stroke had significantly higher serum cystatin C concentrations compared with the participants without ischemic stroke (pooled mean difference, 0.11; 95% confidence interval (CI), 0.00-0.22; P = 0.04), in particular acute ischemic stroke and subclinical cerebral infarction (mean difference, 0.23; 95% CI, 0.11-0.36; P = 0.0003 and mean difference, 0.07; 95% CI, 0.05-0.09; P < 0.00001, respectively). Cystatin C was associated with ischemic stroke, and it could be considered a predictor for the risk of ischemic stroke, especially in acute ischemic stroke and subclinical cerebral infarction.Entities:
Keywords: Cystatin C; Ischemic stroke; Meta-analysis; Risk
Mesh：
Substances：
Year: 2019 PMID： 31313057 DOI： 10.1007/s12031-019-01373-1
Source DB: PubMed Journal: J Mol Neurosci ISSN： 0895-8696 Impact factor: 3.444